Preeti Shashi
A5042996215- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Pregnancy and Medication Impact
- Health Systems, Economic Evaluations, Quality of Life
- Biosimilars and Bioanalytical Methods
- Diverticular Disease and Complications
- Celiac Disease Research and Management
- Gastrointestinal disorders and treatments
- Eosinophilic Disorders and Syndromes
- IL-33, ST2, and ILC Pathways
- Colorectal Cancer Screening and Detection
- Pelvic and Acetabular Injuries
- Tuberculosis Research and Epidemiology
- Esophageal and GI Pathology
- Economic and Financial Impacts of Cancer
- Intraperitoneal and Appendiceal Malignancies
- Systemic Lupus Erythematosus Research
- Colorectal Cancer Surgical Treatments
- Helicobacter pylori-related gastroenterology studies
- Liver Diseases and Immunity
Cleveland Clinic
2017-2020
There are few real-world data on the safety of vedolizumab for treatment Crohn's disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious non-infectious adverse events in clinical practice.We performed a retrospective review from multicenter consortium database (from May 2014 through June 2017). Infectious were defined as those requiring antibiotics, hospitalization, discontinuation, resulting death. Rates proportions per...
Background & AimsWe created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC).MethodsWe performed logistic regression analyses data from the GEMINI 1 trial, 620 patients with UC who received induction maintenance (derivation cohort), identify factors associated corticosteroid-free remission (full Mayo score 2 or less, no subscore above 1). We used these develop model treatment, which we called CDST. evaluated...
Background & AimsPatients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates response to tumor necrosis factor (TNF) antagonists than patients longer duration. Little is known about the association between and other biologic agents. We aimed evaluate CD or UC vedolizumab, stratified by duration.MethodsWe analyzed data from a retrospective, multicenter, consortium (n = 650) 437) treated vedolizumab May 2014 through December 2016. Using time event...
Vedolizumab was demonstrated to be safe and effective in adults with moderately severely active inflammatory bowel disease (IBD) clinical trials. However, there are limited data regarding its efficacy safety elderly patients.This a case-control study comparing the (measured by rates of mucosal healing need for IBD surgery) vedolizumab among patients ≥65 years age (the group) vs those <65 control group). The two groups were matched individually on 1:4 ratio based gender type IBD. Conditional...
Abstract Background Vedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) Crohn’s disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns outcomes of vedolizumab 2 time frames FDA approval. Methods used data sets trend analysis, an academic multicenter consortium (VICTORY) the Truven MarketScan database, periods, May 2014–June 2015 (Era 1) July 2015–June 2017 2). VICTORY...
We aimed to compare the effectiveness of vedolizumab (VDZ) tumour necrosis factor (TNF)-antagonist therapy for Crohn’s disease (CD). Using a multicentre, US-based consortium CD patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting age, sex, prior CD-related hospitalisation within previous year, stricturing penetrating complication history, bowel surgery, severity, steroid refractoriness dependence, and failure. Treatment response was...
We aimed to compare the effectiveness of vedolizumab (VDZ) tumour necrosis factor (TNF)-antagonist therapy for ulcerative colitis (UC). Using a multicentre, US-based consortium UC patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting age, sex, prior UC-related hospitalisation within previous year, disease extent, severity, steroid refractoriness dependence, and failure. Treatment response was categorised using physician global...
We compared the safety profile of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for Crohn's disease (CD) and ulcerative colitis (UC). Using a multicentre US-based consortium CD UC patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting age, sex, prior disease-related hospitalisation within previous year, phenotype (stricturing penetrating complication history CD, extent UC), severity, bowel surgery steroid...
Anastomotic dehiscence and leak are dreaded complications after a colorectal resection can often present with rectal bleeding pelvic abscess or sepsis. Although most cases of gastrointestinal anastomoses minor self-limited, major bleeding, as defined by hemodynamic instability the need for blood transfusions, poses significant challenge management. Here we report case in which patient presenting profuse hematoma secondary to anastomotic was treated endoscopically 50% dextrose spray then enema.
We compared the effectiveness of vedolizumab (VDZ) for Crohn’s disease (CD) and ulcerative colitis (UC) when used alone vs. in combination with an immunomodulator (IM). Using a multicentre US-based consortium Inflammatory Bowel (IBD) patients treated VDZ, we performed propensity score matching concomitant IM use (1:1) accounting CD UC, age, sex, prior disease-related hospitalisation within previous year, severity, steroid refractoriness or dependence, tumour necrosis factor (TNF)-antagonist...
We aimed to quantify rates and identify predictors of serious adverse events (SAE) with vedolizumab (VDZ) for Crohn’s disease (CD) ulcerative colitis (UC). This was a review multicentre, US-based consortium CD UC patients treated VDZ. Serious infections (SI) were defined as those requiring antibiotics or hospitalisation, resulting in discontinuation VDZ death. SAE SI Multivariable logistic regression analyses odds ratio (OR) 95% confidence intervals (CIs) are reported independent SAE. 1087...
Crohn’s disease (CD) patients with shorter duration of have higher response rates to tumour necrosis factor (TNF)-antagonists. Whether improved in early CD is specific TNF-antagonists unknown. We aimed evaluate vedolizumab (VDZ) inflammatory bowel (IBD) stratified by duration. This was a review multi-centre, U.S. based consortium and ulcerative colitis (UC) VDZ treated duration: (≤2 years) vs. late (>2 years). Using time-to-event analyses, we quantified compared remission: clinical (complete...
This is a 32 year old Jewish female seen in our clinic for chronic anemia. She had h/o recurrent gastric ulcers and upper GI bleeds, but no other or constitutional symptoms. Growing up Israel, she two spontaneous perforations. was extensively evaluated-H. Pylori testing +ve twice previously treated appropriately. No NSAID use. Physical exam unremarkable. mild normocytic anemia with normal iron studies B12 levels. Autoimmune workup negative, as work-up Celiac disease Zollinger Ellison...
Introduction: Early experiences after initial availability of drugs are impacted by use in high-risk or refractory patients waiting for alternative therapies (“warehouse effect”). This study aimed to compare treatment pattern and outcomes with vedolizumab (VDZ) over time launch. Methods: A time-trend analysis was performed 2 data sets: 1) VICTORY consortium (n=1,087), a multicenter, tertiary referral center, collaborative cohort VDZ routine practice, 2) Truven MarketScan Database (n=2,574),...
We created and validated a clinical decision support tool (CDST) for vedolizumab (VDZ) therapy in active ulcerative colitis (UC). To identify factors associated with corticosteroid-free remission (CSFREM; full Mayo score ≤2, no sub-score >1), logistic regression analyses were run on data from the GEMINI 1 VDZ trial UC (derivation set; n = 620) used to develop CDST. Correlations between exposure, onset of action, efficacy across predicted-probability groups explored, CDST was externally an...